Creatine Shows Promise for Boosting Brain Function in Early AlzheimerS Trial
LAWRENCE, KS – A newly published, initial-phase trial from the University of Kansas suggests creatine monohydrate may offer a potential avenue for supporting cognitive function in individuals with mild to moderate alzheimer’s disease. The study, published in 2025 in PubMed, involved 20 participants who consumed 20 grams of creatine daily for eight weeks.
Researchers evaluated participants for adherence, safety, changes in brain creatine concentration using magnetic resonance spectroscopy, and cognitive performance. Preliminary results indicated good tolerability and an average 11% increase in brain creatine levels. Modest improvements were also observed in verbal fluency and short-term memory tests.
however, the study authors emphasize the work is a “proof of feasibility” only. The small sample size and lack of a control group preclude definitive conclusions regarding clinical efficacy.
Creatine is one of the most studied supplements, with long-term studies in healthy individuals showing no meaningful toxic effects on the kidneys or liver within recommended doses. “The limitation lies in some specific profiles: individuals with kidney disease or conditions that affect liver function need medical evaluation before using,” notes Diogo Toledo, a researcher familiar with the study. “Another point is that there is no point in overdoing it, because the body has a saturation limit and the excess is eliminated.”
Despite its generally recognized safety, individual variability in creatine uptake and requirements remains uncertain. Long-term effects of continuous, high-dose creatine supplementation are also unknown.
Further research with larger participant groups and extended follow-up periods is crucial to determine optimal dosages, potential differences in effectiveness based on sex and age, and identify which individuals may benefit most. Experts stress the importance of evaluating creatine as part of a complete care plan, rather than a standalone solution.
“It is also essential to evaluate creatine in conjunction with other prevention and treatment strategies, to be seen as part of integrated care, and not as an isolated solution,” says Toledo.
Researcher Arthur Eckert cautions against premature reliance on unproven supplements, warning of the ”possibility cost involved in choices based on unproven promises.” He explains that individuals experiencing cognitive difficulties might delay seeking appropriate medical attention while pursuing unverified remedies.
currently,creatine remains a well-established sports supplement with demonstrated benefits,while its potential as a brain health aid requires further inquiry.
